New findings could help scientists develop treatments for the condition known as ITP.
This collaboration is part of GSK’s “Discovery Partnerships with Academia” (DPAc) efforts.
These findings will help scientists understand how to better diagnose and treat the disease.
Lupu’s findings were published in the Proceedings of the National Academy of Sciences.
QBioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer.
New research will help physicians better identify blood relatives of lupus patients at risk for developing the disease.